Toi M - Search Results

1

Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation.

Iima M, Nakamoto Y, Kanao S, Sugie T, Ueno T, Kawada M, Mikami Y, Toi M, Togashi K. Iima M, et al. Among authors: toi m. J Nucl Med. 2012 Oct;53(10):1534-42. doi: 10.2967/jnumed.111.100958. Epub 2012 Aug 29. J Nucl Med. 2012. PMID: 22933819 Free article.

2

[New molecular target of cancer therapy--angiogenesis regulator VEGF].

Toi M, Ueno T, Tominaga T. Toi M, et al. Gan To Kagaku Ryoho. 1997 Dec;24(15):2202-6. Gan To Kagaku Ryoho. 1997. PMID: 9422062 Review. Japanese.

3

Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer.

Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, Iwanari H, Tominaga T. Toi M, et al. Clin Cancer Res. 1998 Mar;4(3):659-64. Clin Cancer Res. 1998. PMID: 9533534

4

Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer.

Toi M, Ueno T, Matsumoto H, Saji H, Funata N, Koike M, Tominaga T. Toi M, et al. Clin Cancer Res. 1999 May;5(5):1131-7. Clin Cancer Res. 1999. PMID: 10353748

5

Circulating soluble Fas concentration in breast cancer patients.

Ueno T, Toi M, Tominaga T. Ueno T, et al. Among authors: toi m. Clin Cancer Res. 1999 Nov;5(11):3529-33. Clin Cancer Res. 1999. PMID: 10589768

6

Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration.

Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Ueno T, et al. Among authors: toi m. Br J Cancer. 2000 Jul;83(2):164-70. doi: 10.1054/bjoc.2000.1272. Br J Cancer. 2000. PMID: 10901365 Free PMC article.

7

Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer.

Toi M, Bando H, Horiguchi S, Takada M, Kataoka A, Ueno T, Saji S, Muta M, Funata N, Ohno S. Toi M, et al. Br J Cancer. 2004 Jun 14;90(12):2338-43. doi: 10.1038/sj.bjc.6601845. Br J Cancer. 2004. PMID: 15150550 Free PMC article. Clinical Trial.

8

A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer.

Takada M, Kataoka A, Toi M, Bando H, Toyama K, Horiguchi S, Ueno T, Linder S, Saji S, Hayashi Y, Funata N, Kinoshita J, Murakami S, Ohono S. Takada M, et al. Among authors: toi m. Int J Oncol. 2004 Aug;25(2):397-405. Int J Oncol. 2004. PMID: 15254737

9

Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.

Ueno T, Chow LW, Toi M. Ueno T, et al. Among authors: toi m. Biomed Pharmacother. 2006 Jul;60(6):277-9. doi: 10.1016/j.biopha.2006.06.005. Epub 2006 Jun 23. Biomed Pharmacother. 2006. PMID: 16806797 Clinical Trial.

10

The aspartic protease napsin A suppresses tumor growth independent of its catalytic activity.

Ueno T, Elmberger G, Weaver TE, Toi M, Linder S. Ueno T, et al. Among authors: toi m. Lab Invest. 2008 Mar;88(3):256-63. doi: 10.1038/labinvest.3700718. Epub 2008 Jan 14. Lab Invest. 2008. PMID: 18195689 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

786 results

Search Page

Filters